We are live on ! Find out more
INMB icon

INmune Bio

74 hedge funds and large institutions have $7.93M invested in INmune Bio in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 24 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more call options, than puts

Call options by funds: $154K | Put options by funds: $103K

20% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 10

20% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 20

1.61% more ownership

Funds ownership: 17.51%19.12% (+1.6%)

1% more funds holding

Funds holding: 7374 (+1)

18% less capital invested

Capital invested by funds: $9.64M → $7.93M (-$1.71M)

Holders
74
Holders Change
+1
Holders Change %
+1.37%
% of All Funds
0.9%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
24
Reduced
20
Closed
10
Calls
$154K
Puts
$103K
Net Calls
+$51K
Net Calls Change
-$144K

INMB Hedge Fund Activity: Q4 2025 in Review

74 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q4 2025, worth a combined $7.93M — down 18% from $9.64M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new INMB positions and 10 closed out — a net gain of 2 holders — while 24 added to existing stakes and 20 trimmed.

The largest buyer was Dauntless Investment Group, opening a new position worth an estimated $544K. The largest seller was UBS Group, cutting an estimated $169K.

  • 74 institutional investors held INmune Bio (INMB) as of Q4 2025, up from 73 in Q3 2025.
  • Funds reported $7.93M of INmune Bio stock for Q4 2025, down 18% quarter-over-quarter.
  • 12 funds opened new INmune Bio positions in Q4 2025 and 10 closed out, a net change of +2 holders.
  • The largest INmune Bio buyer in Q4 2025 was Dauntless Investment Group, an estimated $544K added.
  • The largest INmune Bio seller in Q4 2025 was UBS Group, an estimated $169K sold.

Based on aggregated 13F filings for Q4 2025.